4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[4-(2,2,2-trifluoroethoxy)-3-trifluoromethylphenyl]benzamide | 851138-07-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[4-(2,2,2-trifluoroethoxy)-3-trifluoromethylphenyl]benzamide
• 英文别名: 4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]-N-[4-(2,2,2-trifluoroethoxy)-3-(trifluoromethyl)phenyl]benzamide
• CAS: 851138-07-3
• 化学式: C₂₆H₁₉F₆N₅O₂
• 分子量: 547.46
• InChiKey: PEERFNZPRBEKBR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  39
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  89
• 氢给体数：
  2
• 氢受体数：
  12

文献信息

• COMBINATIONS COMPRISING BCR-ABL/C-KIT/PDGF-R TK INHIBITORS FOR TREATING CANCER
  申请人：Burke Gregory Peter

  公开号：US20090233905A1

  公开（公告）日：2009-09-17

  The invention relates to a combination comprising a Bcr-Abl, c-Kit and PDGF-R tyrosine kinase inhibitor; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.

  本发明涉及一种组合物，包括Bcr-Abl、c-Kit和PDGF-R酪氨酸激酶抑制剂；以及一种或多种药物活性剂；包括该组合物的制药组合物；包括该组合物的治疗方法；制备该组合物的过程；以及包括该组合物的商业包装。
• Inhibitors of tyrosine kinases
  申请人：NOVARTIS AG

  公开号：EP2100891A1

  公开（公告）日：2009-09-16

  The invention relates to compounds of formula wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, in particular leukaemia, and a method for the treatment of such a disease.

  本发明涉及公式的化合物，其中置换基R1、R2和R4的含义如本发明说明书中所述和解释的那样，以及制备这些化合物的过程，包含它们的制药组合物，其可选择与一个或多个其他药物活性化合物联合使用，用于治疗对蛋白激酶活性抑制有反应的疾病，尤其是肿瘤性疾病，特别是白血病，并且提供了一种治疗这种疾病的方法。
• INHIBITORS OF TYROSINE KINASES
  申请人：Breitenstein Werner

  公开号：US20090286821A1

  公开（公告）日：2009-11-19

  The invention relates to compounds of formula wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, in particular leukaemia, and a method for the treatment of such a disease.

  该发明涉及以下式子的化合物：其中取代基R1、R2和R4的含义如发明说明中所述和解释的那样，以及制备这些化合物的过程，包含这些化合物的药物组合物，与一种或多种其他药物活性化合物结合使用治疗对蛋白激酶活性抑制有反应的疾病，特别是肿瘤性疾病，特别是白血病，以及治疗这种疾病的方法。
• Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
  申请人：Novartis AG

  公开号：EP2314297A1

  公开（公告）日：2011-04-27

  The invention relates to a combination comprising a Bcr-Abl, c-Kit and PDGF-R tyrosine kinase inhibitor; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.

  本发明涉及一种组合物，该组合物包含 Bcr-Abl、c-Kit 和 PDGF-R 酪氨酸激酶抑制剂；以及一种或多种药用活性剂；包含所述组合物的药物组合物；包含所述组合物的治疗方法；制造所述组合物的工艺；以及包含所述组合物的商业包装。
• Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
  申请人：Novartis AG

  公开号：EP2606890A1

  公开（公告）日：2013-06-26

  The invention relates to a combination comprising a Bcr-Abl, c-Kit and PDGF-R tyrosine kinase inhibitor; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.

  本发明涉及一种组合物，该组合物包含 Bcr-Abl、c-Kit 和 PDGF-R 酪氨酸激酶抑制剂；以及一种或多种药用活性剂；包含所述组合物的药物组合物；包含所述组合物的治疗方法；制造所述组合物的工艺；以及包含所述组合物的商业包装。